Patents Assigned to Allergan, Inc.
  • Patent number: 10064872
    Abstract: Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: September 4, 2018
    Assignee: Allergan, Inc.
    Inventors: James Chang, Patrick Hughes, Chin-Ming Chang
  • Patent number: 10065992
    Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: September 4, 2018
    Assignee: Allergan, Inc.
    Inventors: Catherine Simone Victoire Frydrych, William Robert Carling, Michael E. Garst, Michael E. Stern, Christopher S. Schaumburg
  • Patent number: 10064921
    Abstract: Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/or a neuropsychiatric disorder.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: September 4, 2018
    Assignee: Allergan, Inc.
    Inventor: Andrew M. Blumenfeld
  • Patent number: 10065984
    Abstract: Provided herein are multiple solid forms of a defined steroid-like compound, and methods for the preparation and use thereof. In one aspect, there is provided a crystalline form of said steroid-like compound, and methods for the preparation and use thereof. In another aspect, there is provided a substantially amorphous form of said steroid-like compound, and methods for the preparation and use thereof. In yet another aspect, there are provided compositions containing compounds according to the present invention. In certain aspects, such compositions are suitable for delivery of active agents according to the present invention to a subject in need thereof. In another aspect of the invention, there are provided methods for the treatment of a variety of indications, including glaucoma, ocular hypertension, and the like. In still another aspect of the present invention, there are provided kits containing compounds according to the present invention and/or compositions containing same.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: September 4, 2018
    Assignee: ALLERGAN, INC.
    Inventors: Shaoxin Feng, Scott W. Smith, Olivier M. G. Lambert, Suzanne M. Buttar
  • Patent number: 10058560
    Abstract: The present invention is directed to preservative-free solutions of bimatoprost and timolol for lowering intraocular pressure and treatment of glaucoma.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: August 28, 2018
    Assignee: ALLERGAN, INC.
    Inventors: Sukhon Likitlersuang, Ajay Parashar, Chetan P. Pujara, William F. Kelly, Jie Shen, Marina Bejanian, Rhett Schiffman
  • Patent number: 10052192
    Abstract: A breast implant is provided which includes a filling, or core having a lower overall density relative to silicone gel-filled or saline-filled implant. The core may be a composite including flexible, bodies, for example, air-containing, or gas-containing, bodies, and a gel medium between or around the bodies.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: August 21, 2018
    Assignee: Allergan, Inc.
    Inventor: David Schuessler
  • Patent number: 10052190
    Abstract: A laminate useful as a component of a medical implant, for example, useful as a component of an inflatable tissue expander. The laminate includes a base layer, an intermediate layer, and a top layer. When used as a component of a tissue expander, the laminate enables an internal chamber pressure of about 2.5 psi with an expander exterior compressive force of about 40 lbs.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: August 21, 2018
    Assignee: Allergan, Inc.
    Inventors: Kaustubh S. Chitre, Nicholas Manesis, Nikhil S. Trilokekar, Dustin Leslie, David J. Schuessler
  • Patent number: 10045997
    Abstract: New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional manufacturing techniques, and can be easily and conveniently practiced, for example, using application or administration techniques or methodologies which are substantially similar to those employed with prior compositions used to treat ocular hypertension.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: August 14, 2018
    Assignee: ALLERGAN, INC.
    Inventors: June Chen, David F. Woodward, Alexander B. Kharlamb
  • Patent number: 10034923
    Abstract: The invention provides compositions and methods for treating incontinence associated with sexual activity.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: July 31, 2018
    Assignee: Allergan, Inc.
    Inventor: Mitchell F. Brin
  • Patent number: 10029048
    Abstract: Described herein are assisted syringes. The syringes provide a higher force to the plunger tip than the extrusion force applied to the plunger. The assisted syringes can be used to inject or extrude viscous materials.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: July 24, 2018
    Assignee: Allergan, Inc.
    Inventors: Jason S. Metzner, Zachary Dominguez, Justin J. Schwab, Ethan Franklin, Mike Augarten
  • Patent number: 10017541
    Abstract: Disclosed herein are methods of making cyclosporin A Form 2.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: July 10, 2018
    Assignee: Allergan, Inc.
    Inventors: Ke Wu, Scott W. Smith
  • Patent number: 10011593
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: July 3, 2018
    Assignee: ALLERGAN, INC.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang, Sandhya Rao, Rong Yang
  • Patent number: 9980974
    Abstract: Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: May 29, 2018
    Assignee: Allergan, Inc.
    Inventors: Alazar N. Ghebremeskel, Michael R. Robinson
  • Patent number: 9981938
    Abstract: Disclosed herein are compounds according to Formulas 1-12, compositions comprising these compounds, and methods of lowering intraocular pressure (IOP) or causing hair growth, and methods of using the same.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: May 29, 2018
    Assignee: ALLERGAN, INC.
    Inventors: Robert M. Burk, David W. Old, Wha Bin Im, Richard S. Graham, Mu-Lan Lee
  • Patent number: 9981022
    Abstract: A thermo-reversible thermoplastic pharmaceutical composition, comprising a botulinum toxin and a biocompatible poloxamer which provides thermoreversibility to the composition and additionally stabilizes the botulinum toxin, is described. The pharmaceutical composition can be administered to a patient as a liquid, and gels after administration into a sustained release drug delivery system from which the biologically active botulinum toxin is released over a multi-day period thereby localizing the drug as a depot and controlling release to enhance the therapeutic effect per dose.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: May 29, 2018
    Assignee: Allergan, Inc.
    Inventor: Terrence J. Hunt
  • Patent number: 9974773
    Abstract: The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: May 22, 2018
    Assignee: Allergan, Inc.
    Inventors: Pramod Sarpotdar, Kevin Warner, Steven Zhang, Gurpreet Ahluwalia, Amy Kuang
  • Patent number: 9974772
    Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: May 22, 2018
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Patent number: 9962464
    Abstract: Provided are injectable, hyaluronic acid-based dermal filler compositions including conjugated vitamin C derivatives. The compositions provide for extended release of active vitamin C into tissue, promoting collagenesis and other benefits to skin.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: May 8, 2018
    Assignee: Allergan, Inc.
    Inventors: Futian Liu, Xiaojie Yu, Jessamine P. Winer-Jones, Nicholas J. Manesis, Hengli Liu, Gabriel Njikang, Athene Wan Chie Chan
  • Patent number: 9950092
    Abstract: The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions which are particularly advantageous for correction of fine lines in the face.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: April 24, 2018
    Assignee: Allergan, Inc.
    Inventors: Gabriel N. Njikang, Xiaojie Yu, Futian Liu, Sumit Paliwal, Nicholas J. Manesis
  • Patent number: 9943576
    Abstract: Pharmaceutical formulations comprising a clostridial derivative and a permeabilizing agent for intravesical instillation are disclosed.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: April 17, 2018
    Assignee: Allergan, Inc.
    Inventors: Eric A. Forssen, Patrick M. Hughes, David C. Rupp, Terrence Hunt, Gary Shimizu, Joseph Francis, Ron S. Broide, Ester Fernandez-Salas